Cost-Utility Analysis of Mycophenolate Mofetil versus Methotrexate for Noninfectious Uveitis.

Hasenin Al-khersan,Benjamin J Fowler,Kevin D. Clauss,Anne L Kunkler,Nicolas A. Yannuzzi,Nimesh A. Patel,Jayanth Sridhar,Thomas A. Albini,William E. Smiddy

Cost-Utility Analysis of Mycophenolate Mofetil versus Methotrexate for Noninfectious Uveitis.

2021

Hasenin Al-khersan
Benjamin J Fowler
Kevin D. Clauss
Anne L Kunkler
Nicolas A. Yannuzzi
Nimesh A. Patel
Jayanth Sridhar
Thomas A. Albini
William E. Smiddy

Abstract A cost-utility analysis of methotrexate (MTX) versus mycophenolate mofetil (MMF) for noninfectious intermediate, posterior, and panuveitis using data from the FAST Uveitis Trial showed MTX to have a lower cost/QALY, but both are cost-effective.

Keywords:

Methotrexate
Cost–utility analysis
Uveitis
infectious uveitis
Ophthalmology
Mycophenolate
Panuveitis
Medicine
lower cost
Dermatology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations